A patient experiences a sudden episode of severe anxiety. Of these medications in the patient's medical record, which is most appropriate to give as a prn anxiolytic?

Choice A reason: Tranylcypromine is a Monoamine Oxidase Inhibitor (MAOI) used primarily for treatment-resistant depression. It has a slow onset of action, requiring weeks to reach therapeutic levels, and carries significant risks of hypertensive crises if dietary tyramine is ingested, making it entirely inappropriate for acute, as-needed (PRN) use. Choice B reason: Buspirone is an anxiolytic that lacks the sedative or muscle-relaxant properties of benzodiazepines. However, its primary drawback in an acute setting is that it requires 2 to 4 weeks of consistent daily dosing to achieve an effective therapeutic response. It cannot provide the immediate relief required for a sudden anxiety episode. Choice C reason: Lorazepam is a high-potency, intermediate-acting benzodiazepine that enhances the inhibitory effects of gamma-aminobutyric acid (GABA) in the central nervous system. It has a rapid onset of action, typically within 15 to 30 minutes, making it the gold standard for the immediate pharmacological management of acute severe anxiety or panic. Choice D reason: Phenelzine is another MAOI antidepressant. Like tranylcypromine, it is not an anxiolytic for acute distress. Using an MAOI as a PRN would be dangerous and ineffective, as these drugs work by permanently inhibiting enzymes over time rather than providing immediate modulation of the neurotransmitters responsible for the acute stress response.